Alphaeon Corp. has entered into a definitive agreement to acquire all of the outstanding shares and assets of Clarion Medical for an undisclosed sum.
Irvine, CA-Alphaeon Corp. has entered into a definitive agreement to acquire all of the outstanding shares and assets of Clarion Medical Technologies for an undisclosed sum.
The acquisition is expected to close on or before Sept. 30.
“Over the past 25 years, Clarion has shown consistent and profitable growth,” said Robert E. Grant, chief executive officer of Alphaeon. “This acquisition expands (our) geographic reach and provides early market experience with leading products from around the world, including Teoxane’s full-line of dermal fillers, a strong energy device platform, and multiple ophthalmic technologies that provide patients optimal outcomes.
“We also intend to launch ShoutMD, as well as our portfolio of performance, wellness, and beauty products in Canada through our unique digital selling approach,” he continued. “We look forward to partnering closely with the specialty physicians in Canada to advance patient outcomes and experiences.”
“Clarion prides itself on being a trusted strategic partner to Canada’s leading physicians, which is why it is important for us to select a partner whose values and customer centricity aligns with ours,” said Dan Webb, chief executive officer and founder of Clarion. “We truly believe that together we will be able to continue to offer innovative solutions and best-in-class service to our physicians and their patients.
“Most importantly, this transaction provides Clarion access to the ShoutMD proprietary procial (professional and social) media platform, which enables real-time peer-to-peer engagement with the leading physicians within lifestyle healthcare, around the world,” Webb added.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.